Zhifei Biotechnology Gets COVID-19 Vaccine Approved After Viedoc-powered Study

PRESSRELEASE / March 11, 2022

Zhifei biotech has collaborated with Viedoc to get their COVID-19 vaccine approved in China. The approval consists of the recombinant COVID-19 protein vaccine (CHO cells) (ZF2001), which works to prevent diseases caused by COVID-19. This vaccine is the first approved domestic recombinant COVID-19 protein vaccine in China, jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Zhifei biotech. 

The Clinical Trial data, collected globally and stored in China using Viedoc's EDC system, helped Zhifei biotech complete the trial while complying with Chinese and global regulations. The multi-country phase III trial, conducted on subjects aged 18 and above, revealed a protective effect of 81,44% efficacy against COVID-19 of any severity after three doses. Furthermore, the trial data shows that the vaccine provides good protection for Omicron variants.

Viedoc’s eClinical solutions feature the highest standard in data acquisition, management, and visualization. Viedoc's EDC allows clinical research teams to set up, design, and manage clinical trials in one scalable and fully integrated system with minimal time and effort. The results are more efficient trials with a reduced cost and lower risk.

Mats Klaar, CEO of Viedoc, concludes, ”this study is yet another great example of Viedoc's vision in action—working for a healthier world and for greater discoveries.” 

About Viedoc Technologies:
Viedoc designs engaging software for the life science industry. By accelerating clinical trials on all levels, Viedoc’s solutions support major pharmaceutical, biotech, and medical device companies, as well as renowned research institutions worldwide. Headquartered in Uppsala, Sweden, Viedoc also has offices in America, France, Japan, Vietnam, and China. Since Viedoc’s inception in 2003, over 1 million patients in more than 75 countries have participated in studies powered by Viedoc. Discover more at www.viedoc.com

About Zhifei:

Chongqing Zhifei Biological Products has been in the biological product industry since 2002. The Company achieved an operating income of RMB 13.2 billion in the first half of 2021 with the support of its nearly 4,500 employees based on its registered capital of RMB 1.6 billion and total assets of RMB 23.9 billion. In September 2010, Zhifei was listed on the Shenzhen Stock Exchange (stock code: 300122), becoming the first privately-run vaccine enterprise to be listed on ChiNext. Zhifei has five wholly-owned subsidiaries and a joint-stock subsidiary, of which Beijing ZhifeiLvzhu Biopharmaceutical Co., Ltd. and Anhui ZhifeiLongcom Biopharmaceutical Co., Ltd. are new high-tech enterprises.

Read more about the Viedoc solution here.